Literature DB >> 25863041

Lipoprotein lipase deficiency: clinical, biochemical and molecular characteristics in three patients with novel mutations in the LPL gene.

H Kolářová1, M Tesařová1, Š Švecová1, V Stránecký2, A Přistoupilová2, T Zima3, J Uhrová3, S Y Volgina4, J Zeman1, T Honzík1.   

Abstract

Lipoprotein lipase (LPL) deficiency, caused by mutations in the LPL gene, is a rare autosomal recessive disorder manifesting in early childhood with recurrent abdominal pain, hepatosplenomegaly, acute pancreatitis, lipaemia retinalis and eruptive xanthomas. Typical laboratory findings are lactescent serum, extreme hypertriglyceridaemia and hypercholesterolaemia. The diagnostics is based on postheparin serum LPL assay and DNA analyses of the LPL gene. We report clinical, biochemical and molecular data of three children with LPL deficiency. One child manifested since the first week of life with recurrent abdominal pain (Patient 1), the second with abdominal distension and hepatosplenomegaly since the second month of life (Patient 3) and patient 2, asymptomatic younger brother of patient 1, was diagnosed in the first week of life. Lipaemia retinalis and splenomegaly were present in two symptomatic children, hepatomegaly in patient 3 and acute pancreatitis in patient 1. All children had lactescent serum, profound hypertriglyceridaemia (124 ± 25 mmol/l; controls < 2.2), hypercholesterolaemia (22.8 ± 7.3 mmol/l, controls < 4.2) and their LPL immunoreactive mass in serum did not increase after heparin injection. Molecular analyses revealed that both siblings are homozygous for novel mutation c.476C > G in the LPL gene changing the conserved amino acid of the catalytic centre. The third patient is a compound heterozygote for mutations c.604G>A and c.698A>G in the LPL gene, both affecting highly conserved amino acids. We conclude that LPL deficiency must be considered in neonates and young infants with abdominal pain and hypertriglyceridaemia because early treatment might prevent development of life-threatening acute pancreatitis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25863041

Source DB:  PubMed          Journal:  Folia Biol (Praha)        ISSN: 0015-5500            Impact factor:   0.906


  6 in total

1.  Lipid and lipoprotein abnormalities in acute lymphoblastic leukemia survivors.

Authors:  Sophia Morel; Jade Leahy; Maryse Fournier; Benoit Lamarche; Carole Garofalo; Guy Grimard; Floriane Poulain; Edgard Delvin; Caroline Laverdière; Maja Krajinovic; Simon Drouin; Daniel Sinnett; Valérie Marcil; Emile Levy
Journal:  J Lipid Res       Date:  2017-03-08       Impact factor: 5.922

2.  Homozygous LPL p.Gly188Glu Mutation in a Mexican Girl With Lipoprotein Lipase Deficiency.

Authors:  Ana Gabriela Colima Fausto; Juan Ramón González García; Teresita De Jesús Hernández Flores; Norma Alejandra Vázquez Cárdenas; Nery Eduardo Solís Perales; María Teresa Magaña Torres
Journal:  Ann Lab Med       Date:  2017-07       Impact factor: 3.464

Review 3.  Genetic determinants of inherited susceptibility to hypercholesterolemia - a comprehensive literature review.

Authors:  C S Paththinige; N D Sirisena; Vhw Dissanayake
Journal:  Lipids Health Dis       Date:  2017-06-02       Impact factor: 3.876

4.  Rare novel LPL mutations are associated with neonatal onset lipoprotein lipase (LPL) deficiency in two cases.

Authors:  Yun Qin Wu; Yue Yuan Hu; Gui Nan Li
Journal:  BMC Pediatr       Date:  2021-09-20       Impact factor: 2.125

5.  Cell therapy could be a potential way to improve lipoprotein lipase deficiency.

Authors:  Wenjing Wu; Yajun Yin; Jie Zhong; Yongjia Peng; Shuncai Li; Libin Zheng; Hong Cao; Jin Zhang
Journal:  Lipids Health Dis       Date:  2017-10-02       Impact factor: 3.876

Review 6.  Protein Aggregation in the ER: Calm behind the Storm.

Authors:  Haisen Li; Shengyi Sun
Journal:  Cells       Date:  2021-11-28       Impact factor: 7.666

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.